GlassScriptPhysician profile
Ana C Benitez
NPI 1285196923
$4,364.99
in general payments reported to CMS, 2019-2025
31 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.78 · 2023: $1,500 · 2024: $1,835 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,353.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,142.73 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $415.85 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $355.25 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $322.10 | 2023-2025 | |
| Glaxosmithkline, LLC. | $286.33 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $214.09 | 2023-2024 | Dalvance, Avycaz, Ubrelvy |
| Esperion Therapeutics, INC. | $210.40 | 2023-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.91 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $186.51 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $180.38 | 2023-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $121.67 | 2023 | Belsomra, Steglatro, Steglujan |
| Smith+Nephew, INC. | $94.53 | 2024 | Grafix Pl |
| Medtronic, INC. | $86.42 | 2025 | Venaseal |
| Sumitomo Pharma America, INC. | $82.22 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.87 | 2023-2024 | Cycloset, Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $49.15 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $47.57 | 2025 | Veozah |
| Amgen INC. | $40.69 | 2022-2024 | Repatha, Otezla |
| Philips North America LLC | $39.34 | 2025 | Vest Therapy Und |
| Abiomed | $25.98 | 2025 | |
| Corcept Therapeutics | $24.68 | 2025 | Korlym |
| Inari Medical, INC. | $24.20 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Paratek Pharmaceuticals, INC. | $22.59 | 2023 | Nuzyra |
| Janssen Pharmaceuticals, INC | $20.44 | 2023 | Xarelto |
| Tactile Systems Technology INC | $19.22 | 2025 | Flexitouch Plus, Nimbl |
| Horizon Therapeutics Plc | $16.38 | 2023 | Tepezza |
| Phathom Pharmaceuticals, INC. | $16.33 | 2025 | Voquezna |
| Currax Pharmaceuticals LLC | $14.76 | 2025 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $14.71 | 2024 | Trintellix |
| Shield Therapeutics INC | $13.60 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Benitez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.